Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ADX10059: Additional Phase IIa data

Additional data from a French Phase IIa trial in 24 patients showed that 250 mg of oral

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE